Glurenorm

Glurenorm is a prescription tablet that contains the active ingredient gliquidone, a second‑generation sulfonylurea used to manage blood glucose levels in adults with type 2 diabetes mellitus. The medication is supplied as oral tablets, marketed in the European Union, and belongs to the antidiabetic, oral hypoglycemic therapeutic class. It works by stimulating insulin release from pancreatic β‑cells. The dose is individualized based on blood‑glucose monitoring and renal function.

Glurenorm (gliquidone) is indicated for the oral management of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient.

- Used as monotherapy in patients newly diagnosed with type 2 diabetes. - Added to metformin or other oral agents when glycemic control is inadequate. - May be prescribed when insulin therapy is not yet required. - Utilized in combination with lifestyle modifications to achieve target HbA1c levels.

Like other sulfonylureas, gliquidone can cause a range of adverse effects, most of which are related to its insulin‑stimulating action. The frequency and intensity of these events vary with dose, renal function, and concomitant medications.

Common: - Mild hypoglycemia, especially if meals are missed or delayed. - Nausea or gastrointestinal discomfort. - Headache or dizziness. - Weight gain due to increased caloric storage.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions such as skin rash, pruritus, or angio‑edema. - Hepatic dysfunction manifested by jaundice or elevated liver enzymes.

When prescribing Glurenorm, clinicians should evaluate several patient‑specific factors to minimize risk and ensure safe use.

- Assess renal and hepatic function before initiation and periodically during therapy. - Use lower starting doses in elderly patients or those with impaired kidney function. - Monitor blood glucose closely to detect hypoglycemia, especially during dose adjustments. - Advise patients to maintain regular meal patterns and avoid excessive alcohol consumption. - Caution in patients with a history of cardiovascular disease or arrhythmias. - Discontinue or adjust dose if severe hypoglycemia occurs.

Gliquidone may interact with other medicines that affect blood glucose or hepatic metabolism, requiring dose adjustments or monitoring.

Avoid: - Concurrent use with other sulfonylureas or insulin, which can markedly increase hypoglycemia risk. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that raise gliquidone plasma levels.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can potentiate hypoglycemic effects. - NSAIDs or aspirin, which may affect renal function and glucose control. - Oral contraceptives or hormone replacement therapy, which may alter drug metabolism.